U.S. Specialty Stores Stock News

NYSE:BE
NYSE:BEElectrical

US Stock Market Today S&P 500 Futures Rise As Rate Pressure Eases

The Morning Bull - US Market Morning Update Wednesday, Apr, 1 2026 US stock futures are pointing higher this morning, with E mini S&P 500 contracts up about 0.5% and Nasdaq 100 futures rising roughly 0.7%, as investors react to cooler bond markets and mixed global growth signals. The US 10 year Treasury yield is at 4.28%, which means borrowing costs are still relatively high but not pushing higher, easing some pressure on rate sensitive areas like real estate and smaller companies. At the...
NasdaqGS:PGEN
NasdaqGS:PGENBiotechs

Assessing Precigen (PGEN) Valuation After Wider 2025 Loss And Earnings Release

Earnings results bring Precigen’s 2025 performance into focus Precigen (PGEN) recently reported full year 2025 results, with revenue of US$9.68 million and a net loss of US$250.64 million. The wider loss and revenue figures are likely central to how investors reassess the stock. See our latest analysis for Precigen. Precigen’s share price has been volatile, with a 1 day share price return of 19.08% and 7 day return of 23.64%, while the 90 day return shows a decline of 7.42%. This contrasts...
NasdaqGM:CAMT
NasdaqGM:CAMTSemiconductor

Is Camtek (CAMT) Quietly Redefining Its AI Packaging Edge With New CoWoS-Like Orders?

Camtek Ltd. recently announced it received a multi-system order worth US$31 million from a leading OSAT for CoWoS-like packaging geared toward AI applications, bringing first-quarter 2026 OSAT orders to over US$90 million, with systems scheduled for delivery within this year. This surge in advanced packaging demand from outsourced assembly and test providers highlights Camtek’s growing role in inspection and metrology for AI-focused semiconductor manufacturing workflows. Next, we’ll assess...
NYSE:LII
NYSE:LIIBuilding

A Look At Lennox International (LII) Valuation After Conflict Easing Hopes And Stabilizing Oil Prices

Lennox International (LII) moved higher after reports that President Trump was considering ending the military conflict in Iran, along with stabilizing oil prices that eased worries about energy costs and industrial disruptions. See our latest analysis for Lennox International. Lennox’s 4.54% 1 day share price gain to US$464.13 follows improving sentiment around conflict risks and energy costs. However, this comes after an 18.57% 30 day share price decline and a 16.79% 1 year total...
NYSE:SCCO
NYSE:SCCOMetals and Mining

Southern Copper (SCCO) Is Up 7.6% After Unveiling US$19.9 Billion Decade-Long Copper Expansion Plan

Recently, Southern Copper outlined a long-term plan to invest nearly US$19.90 billion over the next decade to lift copper production toward about 1.6 million tons annually by 2035, even as it anticipates near-term output pressure from weaker ore grades at its Peruvian mines. This commitment highlights how one of the industry’s largest reserve holders is positioning itself to be a major future supplier of copper-intensive, energy-transition materials. We’ll now examine how Southern Copper’s...
NYSE:ALL
NYSE:ALLInsurance

Assessing Allstate (ALL) Valuation After Recent Flat Trading And Modest One Month Decline

Why Allstate stock is on investors’ radar today Allstate (ALL) is drawing fresh attention after recent trading left the shares with a return of about flat over the past week and a roughly 3% decline over the past month. See our latest analysis for Allstate. At a share price of US$207.34, Allstate’s recent 3.4% 1 month share price decline comes against a steadier backdrop, with a 1.7% year to date share price return and a 5 year total shareholder return of 98.5% that may hint at mixed momentum...
NasdaqGS:AMZN
NasdaqGS:AMZNMultiline Retail

Is It Time To Reassess Amazon.com (AMZN) After Its Recent DCF Valuation Gap?

For investors wondering whether Amazon.com is fairly priced at around US$208 per share or if the market is missing something, this article explains what the current valuation signals may be indicating. The stock has been relatively flat over the past month with a 0.1% decline. It still shows a 6.3% return over the last year and a 106.0% return over three years, which may raise questions about whether the recent share price reflects its longer term performance. Recent headlines have focused...
NYSE:BNL
NYSE:BNLREITs

A Look At Broadstone Net Lease (BNL) Valuation As Shares Trade Near Recent Levels

Broadstone Net Lease (BNL) has drawn investor attention after recent share price moves, with the stock closing at $18.27 and showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Broadstone Net Lease. While the 1 day and 1 month share price returns of 1.67% and 5.78% declines point to some cooling in the near term, the 90 day share price return of 5.18% and 1 year total shareholder return of 14.25% suggest momentum has built over a longer stretch as...
NYSE:PRLB
NYSE:PRLBMachinery

Proto Labs (PRLB) Valuation Check As Record Revenue And EPS Guidance Beat Expectations

Proto Labs (PRLB) is back in focus after reporting record quarterly revenue, 12.1% year over year revenue growth, and earnings that came in ahead of market expectations, along with guidance that topped EPS forecasts. See our latest analysis for Proto Labs. Despite the upbeat earnings news, Proto Labs has had a mixed share price run, with a 12.71% 90-day share price return and an 11.04% year-to-date share price return. The 1-year total shareholder return sits at 61.12% and the 3-year total...
NasdaqGS:MASI
NasdaqGS:MASIMedical Equipment

Is It Too Late To Consider Masimo (MASI) After This Year’s 40% Rally?

If you are wondering whether Masimo at around US$177.87 is offering value or asking you to pay up for quality, this breakdown will help you frame that question clearly. The stock has been relatively steady over the last week with a 0.5% decline, modestly higher over 30 days with a 1.4% gain, and much stronger year to date with a 39.6% return, compared with a 6.1% return over the past year and a 24.2% decline over five years. Recent headlines have focused on Masimo's position in medical...
NasdaqGM:PSNY
NasdaqGM:PSNYAuto

Volvo Equity Swap And US Production Shift Recast Polestar Risk Profile

Volvo Cars has converted its outstanding shareholder loans to Polestar Automotive Holding UK (NasdaqGM:PSNY) into equity, changing the mix of Polestar’s capital structure. The two companies also agreed to concentrate future manufacturing of the Polestar 3 in the U.S., expanding their existing production collaboration. For investors watching NasdaqGM:PSNY, these moves come against a backdrop of a share price at $18.42 and a long term track record that includes a 41.5% decline over the past...
NYSE:TEX
NYSE:TEXMachinery

Assessing Terex (TEX) Valuation After Recent Share Price Cooling

Terex stock: context for recent performance Terex (TEX) has drawn fresh attention after recent share price moves, with the stock up 0.8% over the past day, showing a 14% decline over the past month and a 10.7% gain over the past 3 months. See our latest analysis for Terex. That 7.7% 1 day share price return sits against a 14.1% 30 day share price decline and a 57.4% 1 year total shareholder return, which suggests momentum has cooled recently after a strong run for longer term holders. If...
NYSE:CDE
NYSE:CDEMetals and Mining

Is It Too Late To Consider Coeur Mining (CDE) After A 236% One Year Surge?

Wondering if Coeur Mining at around US$18.77 is still giving you fair value, or if the big moves are already priced in? This article breaks down what the current market price might be implying. The stock has produced a 236.4% return over the last year and 342.7% over 3 years, while more recently showing a 2.5% return over 7 days, a 30.9% decline over 30 days, and a 7.0% return year to date. This mix of results may signal changing expectations around risk and reward. Recent coverage has...
NYSE:WY
NYSE:WYSpecialized REITs

How Projected Q1 2026 Profit Decline vs. 2026–27 Outlook Will Impact Weyerhaeuser (WY) Investors

Weyerhaeuser recently drew investor attention ahead of its past Q1 2026 earnings release, as analysts projected a sharp year-over-year drop in funds from operations and weaker quarterly profit. At the same time, analysts’ expectations for stronger funds from operations and earnings per share in fiscal 2026 and 2027 have raised questions about how short-term pressure might contrast with the longer-term outlook for the timber REIT. Next, we’ll examine how the expected Q1 2026 profit drop and...
NasdaqGS:NTRA
NasdaqGS:NTRABiotechs

Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)

Natera, Inc. recently reported Clinical Cancer Research data showing its Signatera molecular residual disease test helped older women with early-stage ER+/HER2- breast cancer use primary endocrine therapy instead of surgery, with testing done at baseline and then every 3–6 months. The study’s ability to identify patients who remained progression-free and to detect molecular signs of tumor progression before imaging highlights Signatera’s potential role in personalized treatment decisions for...
NYSE:CRS
NYSE:CRSAerospace & Defense

Assessing Carpenter Technology (CRS) Valuation After Powerful Multi‑Year Shareholder Returns

Carpenter Technology (CRS) is back on investors’ radar after recent share price moves, with the stock closing at $394.15. That level is drawing fresh interest in its long term return profile. See our latest analysis for Carpenter Technology. The recent 6.3% 1 day share price return sits against a quieter 30 day share price return and a stronger 90 day gain of 25.2%, while the 1 year total shareholder return is very large and the 3 and 5 year total shareholder returns are each more than 8x...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

A Look At Recursion Pharmaceuticals (RXRX) Valuation As Investor Narratives Diverge

Why Recursion Pharmaceuticals is on investors’ radar today Recursion Pharmaceuticals (RXRX) has attracted attention after recent trading, with the share price at $3.07 and returns showing mixed performance over the past week, month and past 3 months. For investors tracking high risk biotech names, the company’s clinical stage drug discovery pipeline, revenue of $74.681 million, and market cap of about $1.5b provide context for assessing whether the current level looks appealing or...
NYSE:TDG
NYSE:TDGAerospace & Defense

How Investors May Respond To TransDigm Group (TDG) Beating Q1 Revenue And Operating Income Expectations

In the past quarter, TransDigm Group reported a 13.9% year-on-year revenue increase and exceeded analyst expectations on both sales and adjusted operating income, which management described as a solid start to its 2026 fiscal year. This performance highlights the breadth of TransDigm’s installed base, with its proprietary components touching nearly all in-service aircraft across commercial and military aviation. Next, we’ll examine how TransDigm’s stronger-than-expected revenue and operating...
NasdaqGS:AXON
NasdaqGS:AXONAerospace & Defense

Has Axon Enterprise (AXON) Pulled Back Enough After Recent Product Rollouts And Contract Wins

If you are wondering whether Axon Enterprise at around US$424.69 still offers value or has run ahead of itself, you are not alone. The stock has recently seen a 7% decline over the last week, a 21.7% decline over the last month and a 24.6% decline year to date, even though the 1 year return sits at 21.5% and the 3 year and 5 year returns are 90.4% and 191.7% respectively. Recent headlines around Axon have focused on product rollouts, contract wins with law enforcement agencies and ongoing...